References
-
1
Yamaji Y, Watabe H, Yoshida H. et al .
High-risk population for gastric cancer development based on serum pepsinogen status and lifestyle factors.
Helicobacter.
2009;
14
81-86
-
2
Comfort M W.
Gastric acidity before and after development of gastric cancer: its etiologic, diagnostic and prognostic significance.
Ann Intern Med.
1951;
36
1331-1348
-
3
Miki K, Urita Y.
Using serum pepsinogens wisely in a clinical practice.
J Dig Dis.
2007;
8
8-14
-
4
Watabe H, Mitsushima T, Yamaji Y. et al .
Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study.
Gut.
2005;
54
764-768
-
5
Ladeiras-Lopes R, Pereira A K, Noqueira A. et al .
Smoking and gastric cancer: systematic review and meta-analysis of cohort studies.
Cancer Causes Control.
2008;
19
689-701
-
6
Graham D Y.
Gastric cancer surveillance or prevention plus targeted surveillance.
Jpn J Helicobacter Res.
2009;
10
9-14
-
7
Yang H B, Sheu B S, Wang S T. et al .
H. pylori eradication prevents the progression of gastric intestinal metaplasia in reflux esophagitis patients using long-term esomeprazole.
Am J Gastroenterol.
2009;
104
1642-1649
-
8
Kuipers E J, Lundell L, Klinkenberg-Knol E C. et al .
Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication.
N Engl J Med.
1996;
334
1018-1022
-
9
Kuipers E J, Klinkenberg-Knol E C, Vandenbroucke-Grauls C M. et al .
Helicobacter pylori in the pathogenesis of atrophic gastritis.
Scand J Gastroenterol Suppl.
1997;
223
28-34
-
10
Graham D Y, Genta R M.
Long-term proton pump inhibitor use and gastrointestinal cancer.
Curr Gastroenterol Rep.
2008;
10
543-547
-
11
Lundell L, Havu N, Miettinen P. et al .
Changes of gastric mucosal architecture during long-term omeprazole therapy: results of a randomized clinical trial.
Aliment Pharmacol Ther.
2006;
23
639-647
-
12
Kakinoki R, Kushima R, Matsubara A. et al .
Re-evaluation of histogenesis of gastric carcinomas: a comparative histopathological study between Helicobacter pylori-negative and H. pylori-positive cases.
Dig Dis Sci.
2009;
54
614-620
-
13
Mesquita P, Raquel A, Nuno L. et al .
Metaplasia – a transdifferentiation process that facilitates cancer development: the model of gastric intestinal metaplasia.
Crit Rev Oncog.
2006;
12
3-26
-
14
Tatematsu M, Tsukamoto T, Inada K.
Stem cells and gastric cancer: role of gastric and intestinal mixed intestinal metaplasia.
Cancer Sci.
2003;
94
135-141
-
15
Graham D Y, Shiotani A.
The time to eradicate gastric cancer is now.
Gut.
2005;
54
735-738
-
16
Meining A, Morgner A, Miehlke S. et al .
Atrophy-metaplasia-dysplasia-carcinoma sequence in the stomach: a reality or merely an hypothesis?.
Best Pract Res Clin Gastroenterol.
2001;
15
983-998
-
17
Ito T, Kobayashi D, Uchida K. et al .
Helicobacter pylori invades the gastric mucosa and translocates to the gastric lymph nodes.
Lab Invest.
2008;
88
664-681
-
18
Petersen A M, Krogfelt K A.
Helicobacter pylori: an invading microorganism? A review.
FEMS Immunol Med Microbiol.
2003;
36
117-126
-
19
Dubois A, Boren T.
Helicobacter pylori is invasive and it may be a facultative intracellular organism.
Cell Microbiol.
2007;
9
1108-1116
-
20
Semino-Mora C, Doi S Q, Marty A. et al .
Intracellular and interstitial expression of Helicobacter pylori virulence genes in gastric precancerous intestinal metaplasia and adenocarcinoma.
J Infect Dis.
2003;
187
1165-1177
-
21
Necchi V, Candusso M E, Tava F. et al .
Intracellular, intercellular, and stromal invasion of gastric mucosa, preneoplastic lesions, and cancer by Helicobacter pylori.
Gastroenterology.
2007;
132
1009-1023
D. Y. GrahamMD
Michael E. DeBakey Veterans Affairs Medical Center
Rm 3A-320 (111D)
2002 Holcombe Boulevard
Houston
TX 77030
USA
Fax: +1-713-790-1040
Email: dgraham@bcm.tmc.edu
